VYNE
Income statement / Annual
Last year (2023), VYNE Therapeutics Inc.'s total revenue was $424,000.00,
a decrease of 11.11% from the previous year.
In 2023, VYNE Therapeutics Inc.'s net income was -$28.45 M.
See VYNE Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$424,000.00
|
$477,000.00
|
$14.76 M
|
$20.99 M
|
$443,000.00
|
$10.64 M
|
$4.58 M
|
$674,000.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$3.35 M |
$1.39 M |
$350,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$424,000.00 |
$477,000.00 |
$11.41 M |
$19.60 M |
$93,000.00 |
$10.64 M |
$4.58 M |
$674,000.00 |
$0.00 |
| Gross Profit Ratio |
1 |
1 |
0.77 |
0.93 |
0.21 |
1 |
1 |
1 |
0 |
| Research and Development
Expenses |
$16.31 M
|
$18.39 M
|
$24.96 M
|
$43.53 M
|
$53.76 M
|
$52.99 M
|
$29.01 M
|
$11.26 M
|
$2.92 M
|
| General & Administrative
Expenses |
$13.38 M
|
$16.39 M
|
$0.00
|
$0.00
|
$22.48 M
|
$12.19 M
|
$5.17 M
|
$3.75 M
|
$1.69 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.38 M
|
$16.39 M
|
$54.48 M
|
$89.54 M
|
$22.48 M
|
$12.19 M
|
$5.17 M
|
$3.75 M
|
$1.69 M
|
| Other Expenses |
$1.39 M |
$363,000.00 |
-$135,000.00 |
$1.11 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$29.68 M |
$34.77 M |
$79.44 M |
$133.08 M |
$76.24 M |
$65.18 M |
$34.18 M |
$15.01 M |
$4.61 M |
| Cost And Expenses |
$29.68 M |
$34.77 M |
$82.79 M |
$134.47 M |
$76.24 M |
$65.18 M |
$34.18 M |
$15.01 M |
$4.61 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$3.09 M |
$517,000.00 |
$264,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$10.81 M |
$5.61 M |
$4.39 M |
$2.54 M |
$3.09 M |
$517,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
-$255,000.00
|
$72,000.00
|
$109,000.00
|
$341,000.00
|
$350,000.00
|
$22,000.00
|
$8,000.00
|
$4,000.00
|
$0.00
|
| EBITDA |
-$29.26 M
|
-$33.93 M
|
-$68.17 M
|
-$112.02 M
|
-$76.24 M
|
-$54.54 M
|
-$29.59 M
|
-$14.33 M
|
-$4.61 M
|
| EBITDA Ratio |
-69 |
-71.14 |
-4.62 |
-5.34 |
-172.1 |
-5.13 |
-6.46 |
-21.26 |
0 |
| Operating Income Ratio
|
-69
|
-71.9
|
-4.61
|
-5.41
|
-172.1
|
-5.13
|
-6.46
|
-21.26
|
0
|
| Total Other
Income/Expenses Net |
$1.39 M
|
$363,000.00
|
-$5.75 M
|
-$142.35 M
|
$2.54 M
|
$3.09 M
|
$517,000.00
|
$264,000.00
|
$0.00
|
| Income Before Tax |
-$27.87 M |
-$33.93 M |
-$73.78 M |
-$255.83 M |
-$73.70 M |
-$51.45 M |
-$29.08 M |
-$14.07 M |
-$4.61 M |
| Income Before Tax Ratio
|
-65.74
|
-71.14
|
-5
|
-12.19
|
-166.37
|
-4.84
|
-6.35
|
-20.87
|
0
|
| Income Tax Expense |
$580,000.00 |
$13,000.00 |
-$448,000.00 |
-$258,000.00 |
-$3.24 M |
$3.09 M |
-$8,000.00 |
$0.00 |
$0.00 |
| Net Income |
-$28.45 M |
-$33.95 M |
-$73.33 M |
-$255.57 M |
-$70.46 M |
-$51.45 M |
-$29.08 M |
-$14.07 M |
-$4.61 M |
| Net Income Ratio |
-67.1 |
-71.16 |
-4.97 |
-12.17 |
-159.06 |
-4.84 |
-6.35 |
-20.87 |
0 |
| EPS |
-2.77 |
-10.65 |
-25.65 |
-141.9 |
-149.48 |
-170.94 |
-101.65 |
-87.78 |
-28.75 |
| EPS Diluted |
-2.77 |
-10.65 |
-25.65 |
-141.9 |
-149.48 |
-170.94 |
-101.65 |
-87.78 |
-28.75 |
| Weighted Average Shares
Out |
$10.27 M
|
$3.19 M
|
$2.86 M
|
$1.80 M
|
$471,388.00
|
$300,954.00
|
$286,037.00
|
$160,266.00
|
$160,266.00
|
| Weighted Average Shares
Out Diluted |
$10.27 M
|
$3.19 M
|
$2.86 M
|
$1.80 M
|
$471,388.00
|
$300,954.00
|
$286,037.00
|
$160,266.00
|
$160,266.00
|
| Link |
|
|
|
|
|
|
|
|
|
